Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 9/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.43 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729583 | 0.85 | CETP (0.64) | CETP | |
| SCHEMBL3554105 | 0.82 | CETP (0.51) | CETPGPBAR1TACR1 | |
| SCHEMBL3552957 | 0.77 | CETP (0.72) | CETP | |
| SCHEMBL14631806 | 0.76 | ALDH1A1 (0.42) | EGFRERBB2 | |
| SCHEMBL3557843 | 0.76 | CETP (0.50) | CETPGPBAR1TACR1 | |
| SCHEMBL3729587 | 0.76 | TACR1 (0.43) | CETPTACR1 | |
| SCHEMBL3551798 | 0.75 | CETP (0.49) | CETPGPBAR1TACR1 | |
| SCHEMBL27823696 | 0.73 | PTGDR2 (0.46) | CETP | |
| SCHEMBL1923803 | 0.72 | GPBAR1 (0.51) | CETPGPBAR1 | |
| SCHEMBL3555402 | 0.71 | TACR1 (0.51) | GPBAR1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1737811-A4 | CETP INHIBITORS | MERCK & CO INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1737811-A1 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100298-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | CETP 1/4885GPBAR1 286/4885TACR1 3645/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | CETP 1/4885GPBAR1 286/4885TACR1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.